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Statement of Translational Relevance 
There is an urgent need to identify predictive biomarkers in inflammatory 
bowel disease-associated colorectal cancers (IBD-CRCs) to individualise the 
current prevention, surveillance and treatment programmes. This analysis 
demonstrates that proximal IBD-CRCs have high mutational rates associated 
with defects in MMR (MLH1 loss) and DNA POLE proofreading function. 
Hypermutation is associated with a predicted higher neo-epitope load, which 
could be exploited using immunotherapies in selected patients with 
hypermutated IBD-CRCs. Prospective studies are required to determine 
whether analysis for loss of MLH1 in surveillance colonic biopsies could 
discriminate those at increased risk of developing CRC, permitting a more 
targeted approach for cancer treatment and surveillance. The identification of 
driver genes in hypermutated IBD-CRCs could also be used to develop 
therapeutic agents targeting the corresponding molecular pathways. Our 
comprehensive analysis of the mutational landscape of IBD-CRCs has 
revealed several novel approaches that may complement and personalise 
surveillance and treatment programmes. 
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Abstract:  
Purpose: Inflammatory bowel disease-associated colorectal cancers (IBD-
CRCs) are associated with a higher mortality than sporadic colorectal 
cancers. The poorly defined molecular pathogenesis of IBD-CRCs limits 
development of effective prevention, detection and treatment strategies. We 
aimed to identify biomarkers using whole exome sequencing of IBD-CRCs to 
guide individualised management.  
Experimental Design: Whole-exome sequencing was performed on 34 
formalin-fixed paraffin-embedded primary IBD-CRCs and 31 matched normal 
lymph nodes. Computational methods were used to identify somatic point 
mutations, small insertions and deletions, mutational signatures, and somatic 
copy number alterations.  Mismatch repair status was examined.  
Results: Hypermutation was observed in 27% of IBD-CRCs. All 
hypermutated cancers were from the proximal colon; all but 1 of the cancers 
with hypermutation had defective mismatch repair or somatic mutations in the 
proofreading domain of DNA POLE. Hypermutated IBD-CRCs had increased 
numbers of predicted neo-epitopes, which could be exploited using 
immunotherapy. We identified 6 distinct mutation signatures in IBD-CRCs, 3 
of which corresponded with known mechanisms of mutagenesis. Driver 
genes were also identified. 
Conclusions: IBD-CRCs should be evaluated for hypermutation and 
defective mismatch repair to identify patients with a higher neo-epitope load 
who may benefit from immunotherapies. Prospective trials are required to 
determine whether immunohistochemistry to detect loss of MLH1 expression 
Research. 
on July 31, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 27, 2018; DOI: 10.1158/1078-0432.CCR-17-3713 
 7 
in dysplastic colonic tissue could identify patients at increased risk of 
developing IBD-CRC. We identified mutations in genes in IBD-CRCs with 
hypermutation that might be targeted therapeutically. These approaches 
would complement and individualise surveillance and treatment programmes. 
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INTRODUCTION 
Inflammatory bowel disease associated colorectal cancer (IBD-CRC) is an 
aggressive complication of chronic inflammation accounting for 10-15% of 
deaths from IBD. IBD-CRC patients are younger and have a higher mortality 
than those with sporadic colorectal cancer (1). IBD-CRC arises diffusely in 
chronically inflamed epithelium via low-grade dysplasia evolving to high-
grade dysplasia and eventually adenocarcinoma, although it may also arise 
without these preceding changes. Technological advances in endoscopy 
have improved the ability to discriminate between normal and pre-cancerous 
mucosa (1), however, a third of cancers arise in the interval between 
scheduled colonoscopies, suggesting poor efficacy of surveillance 
programmes (2). Colonoscopy-directed mucosal samples are analysed for 
the presence of dysplasia, which remains the gold standard for predicting 
future cancer risk in IBD when reported by an expert gastrointestinal 
pathologist.  
The poorly defined molecular and genetic pathogenesis of IBD-CRC impairs 
our ability to detect and treat colorectal cancer effectively. There is an urgent 
need to identify biomarkers to improve early detection of colorectal cancer 
and guide individualised therapy (2).  
We elected to study primary IBD-CRC since molecular changes identified in 
the resected cancer specimen are most likely to represent biomarkers of 
cancer development.  We characterised the hypermutator status of the 
cancers, defined the mutational signatures and underlying biological 
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processes, and explored the potential clinical translation of this work with 
respect to immune therapy, and improving current surveillance programmes.  
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MATERIALS and METHODS 
Ethical Approval and Case Identification 
The study was approved by the Lothian NHS Research Scotland Human 
Annotated BioResource, which is an NHS Health Research Authority Ethics 
Committee-approved Research Tissue Bank (www.hra.nhs.uk; 15/ES/0094) 
for the use off human tissue surplus to diagnostic requirements. The study 
was conducted in accordance with the Declaration of Helsinki and the 
guidance from the Human Tissue Authority on the use of human tissue from 
diagnostic archives. The Lothian (Edinburgh, UK) pathology database was 
searched for IBD-CRCs using the terms inflammatory bowel disease, Crohn’s 
disease, ulcerative colitis, colon cancer, colorectal and rectal cancer between 
1990 and 2011 by the Tissue Bank appointed pathologist and provided the 
anonymised tissue samples with linked clinical data. Two independent expert 
GI pathologists (MJA and CJB) and a specialist IBD Consultant Physician 
(SD) verified the IBD-CRCs following careful review of the patient’s 
anonymised medical records, the histopathological evidence for IBD in 
previous colonic samples and in the IBD-CRC resection specimen.  
Cases were only included from patients with a previous histopathological 
diagnosis of IBD and where evidence of IBD in the resected colonic 
specimen was confirmed by both GI specialist pathologists (CJB and MJA) 
independently. Sporadic adenomas and colorectal cancers which arose in an 
area of the colon without prior evidence of IBD in that colonic area were 
excluded. For each case we have clear histopathological evidence of pre-
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existing IBD at each tumour site and have confirmed that we have selected 
IBD-associated colorectal cancers. 
Formalin fixed paraffin embedded (FFPE) cancer and uninvolved normal 
lymph node blocks, removed at the time of surgery, were sectioned, H&E 
stained and used for further analysis. In total 31 cases (15 Crohn’s Disease 
(CD): 16 Ulcerative Colitis (UC)) with 34 cancers were used in this study.  
 
Clinical Phenotype Data: Statistical Analysis 
The ‘survival’ package within the R software environment (3) was used to 
generate the Kaplan-Meier survival curves and perform statistical analyses. 
Categorical clinical phenotype data was analyzed using the Two-tailed 
Fisher’s exact test; a P-value of <0.05 was considered significant. No survival 
data was available for case 2L (hypermutator) which was excluded from the 
survival analysis. Cases 15G1 and 15G2 were considered as one case for 
the purpose of statistical comparison, as they appear to originate from the 
same precursor clone. 
 
Sequencing Data Generation, Processing and Analyses 
Nucleic acids were extracted using Qiagen Allprep FFPE DNA extraction kits, 
and DNA/RNA was quantified using Agilent GeneChips. For WES, DNA was 
captured using the Agilent SureSelectXT Human All Exon V5 platform 
following the manufacturer’s protocol. Sequencing was performed using the 
Illumina HiSeq 2000 platform at the Wellcome Trust Sanger Institute. Raw 
paired-end sequencing reads (75bp) were aligned and a modified version of 
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the reference genome which includes the GRCh37 primary assembly and 
additional human contigs and viral sequences that reduce the number of 
reads erroneously mapped to the primary assembly. Further details on data 
processing, data quality assessment and sequence alignment are available 
in the Supplementary Materials and Methods. Somatic point mutations and 
small insertions and/or deletions (InDels) were identified by comparing 
cancer and matched normal samples using MuTect (v1.1.7) (4) and Strelka 
(v1.0.14) (5), respectively. BCFtools (v1.3) (6) was used to identify variants in 
each patient’s germline (normal lymph nodes) relative to the human 
reference genome described above. The Ensembl Variant Effect Predictor (7) 
software was used to predict the effect of each variant on protein sequences, 
and the clinical significance of the changes was predicted by comparison to 
variants in the ClinVar database (release date 2016-05-31). For genes with 
multiple transcripts, we report the effect of the variant on the protein derived 
from the canonical transcript as annotated in Ensembl release 81 for 
GRCh37 (Supplementary Table S7; Supplementary Materials and Methods). 
We also provide the predicted effect on all transcripts in Supplementary 
Table S8. The Sequenza software package (version 2.1.2) (8) was used to 
identify somatic copy number alterations. For the non-hypermutator cases, 
MutSigCV (version 1.4) (9), which identifies significantly mutated genes, and 
dNdScv (10), which identifies genes under positive selection in cancer, were 
used to identify driver genes. For the hypermutator cases, microsatellite 
InDels were excluded from analysis with MutSigCV. The microsatellite InDels 
were analysed with a modified version of MSMutSig (11) obtained from the 
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author, along with required input files. In dNdScv, which is able to analyze 
both the SNV and InDel mutations together in both hypermutator and non-
hypermutator cohorts, two InDel models are available; one model considers 
the total number of InDel mutations per gene, and the other model considers 
unique InDel sites per gene (the “unique-sites model”). For the hypermutator 
cohort, dNdScv was run using both models, and the results were compared. 
Only the “unique-sites” model was used for the non-hypermutator cohort. 
Restricted hypothesis testing was performed on the results from dNdScv, 
using known cancer genes from the Cancer Gene Census version 81 (12). 
Further details are available in the Supplementary Materials and Methods. 
Mutation signatures were identified with the Bioconductor package 
SomaticSignatures (version 2.6.0) (13) using the non-negative matrix 
factorization (NMF) algorithm. Details of software parameters, databases 
used, variant annotation, variant filtering, validation and the identification of 
driver genes are available in the Supplementary Materials and Methods. 
 
HLA Typing and Neo-epitope Predictions 
Human leukocyte antigen (HLA)-I 4-digit typing was performed using the 
OptiType 1.0 algorithm and neo-epitopes from missense mutations were 
predicted by mapping the corresponding protein sequences to the human 
proteome database (version GRCh37.74). Neo-epitopes with a relative 
percentile rank ≤ 1% for each HLA-I allele were considered binders 
(additional details are provided in Supplementary Materials and Methods).  
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Mismatch Repair Immunohistochemistry  
Immunohistochemistry for MLH1, MSH2, MSH6 and PMS2 was undertaken 
on a cancer tissue microarray and staining was independently scored by two 
pathologists (MJA and AO). Discordant scores were resolved by staining 
whole tissue sections with additional MLH1, MSH2, MSH6 and/or PMS2 
antibodies. 
 
MLH1 Promoter Methylation Analysis 
MLH1 promoter methylation was analysed using the EZ DNA Methylation Kit 
Gold (Zymo Research). Cases from patient 32N failed methylation analyses.  
Further experimental details are described in the Supplementary Materials 
and Methods.  
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RESULTS 
To identify biomarkers associated with IBD-CRC, WES was performed on 34 
IBD-CRCs and matched normal lymph node pairs. Twenty-nine patients had 
one cancer, one patient had three primary cancers separated anatomically 
(32N) and one patient had two cancers in close proximity to each other (15G) 
(Supplementary Table S1). WES yielded between 45- and 90-fold coverage 
of the cancer samples and 26- and 93-fold coverage of the normal lymph 
node samples (Supplementary Fig. 1). When considering protein coding and 
splice site mutations only, the cancers from 32N had only 6 mutations 
common to at least 2 of the 3 cancers, while the two cancers from 15G had 
over 2345 common mutations (22% of the total mutant positions in these 
cancers).  
 
Somatic Mutation Rates in IBD-CRC  
Somatic point mutations and InDels were identified by comparing exome 
sequences from cancer tissue with those from uninvolved lymph nodes 
removed at the time of surgery (Supplementary Tables S7 - S8).The 34 
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cancers were divided into two groups based on distinct somatic mutation 
rates. There were 24 non-hypermutator cancers with 2.0-7.0 mutations/Mb, 
and 10 hypermutator cancers with 32.6-171.3 mutations/Mb (Fig. 1A and 
Table 1). Two of the 10 cases, 15G1 and 15G2, have a somatic mutation 
burden greater than 100 mutations/Mb and could thus be defined as ultra-
hypermutators. 
The proportion of hypermutators in our IBD-CRC data set was 27%, or 9/33 
(cases 15G1 and 15G2 were counted once, since they appear to originate 
from the same precursor clone) and was not significantly higher than the 16% 
present in a cohort of 382 sporadic CRCs downloaded from The Cancer 
Genome Atlas (TCGA) Data Portal (see Supplementary Materials and 
Methods) (right sided binomial test, P=.07), nor the 28% observed in a larger 
cohort of 619 sporadic CRCs from Giannakis et al. (binomial test, P=1) (14). 
The hypermutator cases had elevated levels of both single nucleotide 
variants (SNVs) and InDels, with the exception of cases 15G1, 15G2 and 6J, 
which have similar InDel mutation rates to the non-hypermutator cases (Fig. 
1A). The median age at diagnosis was not significantly different between the 
hypermutators (median 66.2 years; IQR 57.4-78.1 years) and non-
hypermutators (median 65.8 years; IQR 51.0-77.0 years).  
Overall, there was a significant survival difference between the patients with 
hypermutator cancers and those with non-hypermutator cancers (log rank 
test, P=.04), with the estimated 10-year survival being 75% in the former 
group as compared with 36% in the latter (Fig. 1B). However, it is likely that 
additional factors other than mutator status including stage and age 
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influenced patient survival although we were unable to measure the affects of 
these variables due to the small sample size. 
Strikingly, the hypermutator cancers were all located in the proximal colon 
and none in the distal colon (two-tailed Fisher’s exact test, P=.004) (Fig. 2).  
 
Mismatch Repair Abnormalities 
To characterise the difference in mutational rates, the cancers were analysed 
for genetic aberrations associated with dMMR. Seven out of the ten 
hypermutator cancers had a high frequency of InDels (Fig. 1A), which is 
indicative of MSI, and showed loss of expression of MLH1 and its 
heterodimeric binding partner PMS2 (Fig. 2; Supplementary Fig. 2). Loss of 
MLH1 protein expression results in dMMR, leading to increased somatic 
substitution and susceptibility to cancer (15). Loss of MLH1 expression can 
be explained by MLH1 promoter hypermethylation in 5 of these 7 cancers 
(Fig. 2; Supplementary Fig. S3). One of the two remaining cancers (33W), 
had a somatic nonsense mutation within the ATPase domain (R100*) of the 
MLH1 gene, resulting in a truncated protein with a predicted loss of function. 
We did not find other coding mutations that would cause MLH1 to be 
biallelically inactivated in case 33W. We did not detect any point or InDel 
mutations in MLH1 in the germline or tumour in case 28E, nor epigenetic 
silencing by promoter hypermethylation that could explain the loss of MHL1 
expression in this case. The normal expression of MLH1 and low level of 
somatic InDels in the remaining 3 hypermutator cancers, 15G1, 15G2, and 
6J, point to alternative mechanisms leading to hypermutation. In contrast, 
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loss of expression, promoter hypermethylation and non-silent somatic 
mutations were not observed in MLH1 in the non-hypermutator cases (Fig. 2; 
Supplementary Table S2B).  
 
Mutations in DNA Polymerase Proof-reading Domains 
During DNA replication, DNA fidelity is maintained by the proof-reading 
function of DNA polymerases. Germline mutations in the exonuclease proof-
reading domains of the DNA polymerases POLD1 (codons 245-571) and 
POLE (codons 223-517) have been shown to predispose to the development 
of hypermutated microsatellite stable (MSS) sporadic colorectal cancer (16). 
Non-silent somatic mutations in POLE and POLD1 were identified in 4 and 7 
of the hypermutator cancers, respectively (Fig. 2; Supplementary Table S2A). 
Two shared somatic POLE mutations (P286R and F348S) affected the 
exonuclease proof-reading domain in cases 15G1 and 15G2, which were two 
adjacent cancers (adenocarcinoma and squamous cell carcinoma) in the 
same patient (Fig. 1A; Fig. 2).  
No frameshift or non-silent somatic POLE or POLD1 point mutations were 
identified in the non-hypermutator cancers. 
 
The mechanism of hypermutation in case 6J remains undefined. Case 6J 
was an adenocarcinoma from a patient with a 20 year history of colonic 
Crohn’s disease and autoimmune liver disease for which she received potent 
immunosuppression (prednisolone, tacrolimus and azathioprine) throughout 
this period. This patient had 4 basal and 2 squamous cell carcinomas of skin 
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removed but did not have any frameshift or non-silent somatic or germline 
point mutations in PTCH1, excluding Gorlin syndrome as a contributing factor 
to the underlying cancer predisposition (17). In addition, germline mutations 
that could explain the hypermutator phenotype were not found in other DNA 
repair genes including those involved in nucleotide and base excision. It is 
possible that the continuous, prolonged immunosuppression in this patient 
has altered the immune cancer response resulting in both colonic and 
multiple skin cancers. 
 
Mutational Signatures in IBD-CRC 
It has been demonstrated that different mutational processes in cancers 
generate specific patterns of mutation, or ‘signatures’, with 30 distinct 
signatures identified thus far by Alexandrov et al. (18). The overall mutational 
spectrum our IBD-CRC cohort was very similar to the spectra derived from 
cohorts of sporadic CRCs from Giannakis et al. (14) (cosine similarity=.87) 
and from TCGA Data Portal (cosine similarity=.91) (Fig. 3A; Supplementary 
Materials and Methods). Six distinct signatures, designated A-F, were 
extracted from the catalogue of IBD-CRC somatic mutations (Fig. 3B) and 
corresponded well to Alexandrov Signatures 10, 1, 13/2, 17, 6 and 5, 
respectively, with cosine similarities ranging from .82 to .97 (Fig. 2 lower 
panel; Supplementary Table S3). Some of the signatures have been 
associated with specific mutational mechanisms (18). Of particular note, are 
IBD-CRC Signature A (Alexandrov Signature 10/POLE) that was 
predominant in the hypermutator cancers with DNA POLE mutations (15G1 
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and 15G2); and IBD-CRC Signature E (Alexandrov Signature 6/dMMR and 
MSI) that was predominant in the 7 hypermutator cancers which had loss of 
expression of the MLH1 protein (Fig. 2). IBD-CRC Signature C (Alexandrov 
Signature 13 and 2/AID/APOBEC) is the major contributor in case 21M, 
however as we our analysis is limited to the exome regions only, we have no 
evidence of AID/APOBEC activation in this case. Transcriptional upregulation 
of APOBEC3B is commonly found in bladder, cervical, lung, head/neck and 
breast cancers with kataegis (18),  however, we did not find evidence of 
kataegis in case 21M (Supplementary Fig. S4). It has been hypothesised that 
one cause of APOBEC3B upregulation may be infection by viruses, including 
Human Papillomavirus (HPV) (19). We did not find HPV DNA associated with 
case 21M, however, since whole-exome sequencing was used in this study, 
any viral sequence present would be excluded unless it has integrated into 
the genome in the targeted sequences.   
Although Alexandrov signatures 2 and 13 have not yet been identified in 
CRC, an APOBEC mutation pattern has been found, using different methods, 
in a variety of cancer types including whole-genome sequenced sporadic 
CRCs (20). Signatures 1, 5, 6 and 10 have previously been found in sporadic 
colorectal cancers (18) and signature 17 has been identified in MSS CRC 
(21). Taken together, these results indicate that the mutational mechanisms 
in IBD-CRC and sporadic CRC are similar, although a much larger IBD-CRC 
cohort and whole-genome sequencing may reveal additional or novel 
signatures.  
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Recently, a signature attributed to the persistence of 8-oxoguanine G>T/C>A 
mismatches due to biallelic inactivation of MUTYH has been identified in 
MUTYH-associated polyposis (MAP) CRCs (22). Unsurprisingly, we did not 
find this signature in our IBD-CRCs as our cases did not have a history of 
MAP nor any germline non-silent or splice site point or InDel mutations in 
MUTYH other than common SNPs. We did not discover a novel 
inflammation-associated mutational signature in our cohort. Similarly, others 
have not found an inflammation-signature common to chronic inflammatory-
associated gastrointestinal cancers (such as Barrett’s oesaphagus) (23). 
Rather, epithelial regeneration and the subsequent cumulative effect of 
chronic inflammation-associated damage appears to be a major mechanism 
of promoting carcinogenesis in IBD (24).  
 
Driver Genes in IBD-CRC 
To identify driver genes in non-hypermutator IBD-CRC, we used MutSigCV 
(9) to identify significantly mutated genes, and dNdScv to find genes under 
positive selection in cancer (10) (Methods and Supplementary Materials and 
Methods). In our 24 cases, TP53, PIK3CA, APC, and KRAS were identified 
as driver genes (FDR-adjusted P-value, or q<.10) (Fig. 4A), all of which are 
also driver genes in sporadic CRC (25). As observed in sporadic CRC (25), 
significantly more non-hypermutator cancers had non-silent somatic 
mutations in TP53 than the hypermutator cancers (79% vs. 33%; Two-tailed 
Fisher’s exact test, P=.03) (Table 2). 
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In the hypermutator cases, no driver genes were identified using MutSigCV 
(9) or MSMutsig (11), due to small sample size. When using dNdScv (10), 
followed by restricted hypothesis testing with a list of known cancer genes 
from the Cancer Gene Census (version 81) (12), KRAS (q=.03) was 
identified as a driver gene in the hypermutator cohort, in which 3 of the 4 
cases with KRAS mutations are  p.G12D (Fig. 4A).  Importantly, this analysis 
also identified hotspot InDel mutations in RPL22 (p.K15fs; q=.001), ACVR2A 
(p.K437fs; q=.03) and RNF43 (p.G659fs; q=.1) (Fig. 4A; Supplementary 
Materials and Methods). The same ACVR2A and RNF43 mutations have 
previously been identified as driver events in a much larger cohort of 
sporadic CRC (11), and while they may represent driver events in IBD-CRC, 
they could also be genomic sites that are particularly prone to mutation. A 
much larger cohort of MSI IBC-CRCs would be required to confirm these as 
driver events. As reported for sporadic CRCs (26), we find enrichment of 
RNF43 mutations in MSI cases, and mutual exclusivity of RNF43 truncating 
mutations (which includes frameshift InDels, nonsense mutations and splice 
site mutations) with APC truncating mutations in our IBD-CRC cohort (Fig. 
4A).   
Several of the genes we identified are clinically actionable. For example, 
tumours with RNF43 mutations are sensitive to porcupine inhibitors (27). In 
the same way RPL22 mutant cancers may be susceptible to MDM2-p53 
pathway compounds (28). Notably, the same RPL22 p.K15fs hotspot 
mutation we identified in our IBD-CRC cohort has been frequently found in 
endometrial, gastric and colorectal cancers (28). 
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Somatic IDH1 R132 Mutations 
A potentially targetable IDH1 hotspot mutation at R132, which was mutated 
in 11% (5/47) of IBD-CRCs and only in CD-associated CRCs, was previously 
reported by Yaeger et al. (29). In our cohort, one IDH1 R132C mutation was 
present in UC-associated CRC case 32N3. The observed frequency here is 
not significantly different than that of Yaeger et al. (29) (Chi squared test, 
P=.21).  We note, however, that the median 17-fold coverage (range 9-36-
fold in the tumour samples) at this site was lower than the whole-exome 
median of 70-fold, as this mutation is only 20bp from an exon boundary 
where coverage tends to be lower in whole-exome sequencing studies. 
  
Somatic Copy Number Alterations in IBD-CRC 
As previously observed with sporadic CRC (30), somatic copy number 
alterations (SCNAs) in IBD-CRCs were significantly more prevalent (one-
tailed Student’s t-test P=.001) in the non-hypermutator cases compared with 
hypermutator cases (Supplementary Fig. S5; Supplementary Table S6).  
Robles et al. (31) reported 15 focal copy number gains, 8 of which were 
observed in more than one tumour and Shivakumar et al. (32) reported 26 
focal SCNAs in pooled IBD-associated dysplastic and carcinoma biopsy 
samples. Focal SCNAs common to our IBD-CRC cohort and these studies 
are gains in 12p13.33-12p13.31, 22q11.21, 4p16.3, 8q24.3, 10q26, 13q12, 
20q11.23 and 20q13; however, none were common to all three. 
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We compared the frequency of predicted chromosome arm-level SCNAs to 
recurrent SCNAs found by Sheffer et al. (33), and to SCNAs identified by 
TCGA (25) (Fig. 4B; Supplementary Table S6). Our novel data demonstrate 
that the frequencies of specific arm-level SCNAs in IBD-CRC broadly 
concurs with those found in sporadic CRC (25, 33).  
 
Germline Variants in IBD Patients  
Colorectal cancer affects up to 2.5% of the patients who suffer from IBD (1), 
and germline variations conferring cancer susceptibility have been poorly 
described in this population of patients. We examined the germlines of our 
cohort for variants in genes implicated in susceptibility to colorectal cancer 
(Supplementary Tables S4 - S5). The CHEK2 frameshift mutation at T367 
(c.1100delC; rs555607708), in the germline of case 15N, is known to 
predispose to breast cancer, but association with colon cancer has not been 
resolved (34). The R242H mutation in SDHB (rs74315368) in case 3Q has 
been characterized in paragangliomas (35) but not, to our knowledge, in 
colon cancer. The remaining germline variants we have reported in 
Supplementary Table S5 are in genes known to be associated with increased 
risk of CRC, however, they have unknown or mixed reported clinical 
significance and currently we are unable to clarify as to whether these 
variants confer a predisposition to colorectal cancer in the setting of chronic 
inflammation. 
 
Neo-epitope and Immune Infiltrate Analysis 
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Non-synonymous somatic mutations in cancer can generate novel antigens, 
(neo-epitopes) that can be exploited in cancer immunotherapy. The number 
of predicted neo-epitopes is expected to be directly proportional to the 
mutational load of cancers (36). As expected, the IBD-CRC hypermutator 
cancers generated the largest number of HLA Class I neo-epitopes, and 
were significantly higher than the number found in non-hypermutators (one-
tailed Student’s t-test, P=.004) (Fig. 5). Similar to our study the neo-epitope 
load was higher in sporadic CRC with dMMR/MSI-high status, than in 
pMMR/MSS tumours, and notably, they responded favourably to PD1 
blockade (14). IBD is characterized by a dysregulated immune response and 
many therapeutic modalities targeting inflammation are directed at cytokines. 
Analysis of the cytokine gene immune expression profile demonstrated that 
overall the cytokine gene expression profile was similar in the hypermutator 
IBD-CRCs and the non-hypermutator IBD-CRCs (Supplementary Fig. S6), 
although this analysis was limited by the very small size of tumour epithelium 
(with very little immune cell-containing stroma) sampled. 
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DISCUSSION 
We have undertaken a comprehensive analysis of 34 IBD-CRCs from 31 
patients using WES. Hypermutator cancers were observed in both our study 
and Robles et al. (31) and the mutational rates were within range of the 
larger TCGA sporadic CRC cohort (25).  
In sporadic and hereditary colorectal cancers, the hypermutator phenotype is 
most frequent in cancers of the right (proximal) colon (25) . In this study, we 
observed a strong association between CD-associated CRCs occurring in the 
proximal colon (Two-tailed Fisher’s exact test, P=.03) and the hypermutator 
phenotype (Two-tailed Fisher’s exact test, P=.05. Long standing, extensive 
colonic CD has been shown to be associated with proximal cancers (37) and 
we have clear histopathological evidence of pre-existing IBD at each tumour 
site, more than half of which were in the proximal colon. Similar to previous 
studies of IBD-CRC (38) a higher proportion of UC-associated CRCs 
occurred in the left colon (Fig. 2) when compared with CD-associated CRCs 
(Two-tailed Fisher’s exact test, P=.03) . 
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Previous studies have reported a variable frequency of MLH1 promoter 
hypermethylation and loss of expression of MLH1 in IBD-CRCs (39). The 
frequency of MLH1 promoter methylation in our series may be associated 
with the more advanced age at time of IBD-CRC diagnosis, although it 
remains lower than that of sporadic MSI-high CRC with CpG (MLH1) 
hypermethylation (40). Lennerz et al. (39) have exclusively studied CRC 
complicating Crohn’s colitis and described the median age of cancer 
diagnosis to be 58 years (range 34–77) which is also slightly higher than that 
conventionally reported for IBD-CRCs. In addition to our strict inclusion 
criteria, and similar to previous studies (39), the mutation analysis identified a 
single BRAF V600E mutation in one hypermutator IBD-CRC (Fig. 2) 
confirming that these cancers are unlikely to be sporadic in nature.  
BRAF V600E mutations occur in the majority (>85%) of hypermethylated 
sporadic MSI high CRCs (25) and are therefore established in diagnostic 
algorithms to differentiate between sporadic and familial Lynch Syndrome 
cases of colorectal cancer (41). Notably, we did not identify germline 
mutations in genes such as MLH1, MSH2, APC, and MUTYH that predispose 
to the development of CRC in our IBD-CRC cohort.  Although the  proportion 
of hypermutator cancers in our cohort was not significantly different than that 
in sporadic CRC, these differential mutations distinguish our hypermutated 
IBD-CRC cohort from hypermutated sporadic and familial forms of CRC.  
 
The effect of dMMR/MSI on survival outcomes in IBD-CRC has not been 
reported. A recent meta analysis of 20 studies including 571,278 patients by 
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Reynolds and colleagues (42) has reported that IBD-CRC does not affect the 
overall 5 year survival compared with sporadic CRC without any adjustment 
for molecular subtypes. In our series, the hypermutator IBD-CRCs (which 
included 2 MSS hypermutators 15G and 6J) had a significantly better survival 
compared with non-hypermutator IBD-CRCs. The increased survival of 
sporadic MSI cancers (43) is comparable to the data presented here for IBD-
CRCs. The improved survival of early stage sporadic dMMR/MSI cancers is 
postulated to be mediated by (anti-) tumour infiltrating lymphocytes (TILs) in 
response to the neo-epitopes generated by the high mutational rate. Immune 
blockade therapies targeting immune checkpoints and enhancing the anti-TIL 
response are currently being used in various cancers including CRC (44). In 
our series, the hypermutator IBD-CRCs had a higher predicted neo-epitope 
load but we were unable to identify any obvious differences in the immune 
related gene expression profile. This is unsurprising as our samples had 
been enriched for cancer-containing cells and not the adjacent immune rich 
stromal compartment. Molecular phenotyping of all colorectal cancers for 
targeted therapy is a compelling reason for universal screening for dMMR . 
Of note, the United States Food and Drug Administration has approved 
Pembrolizumab (targeting the programmed cell death 1 receptor) for the 
treatment of all unresectable or metastatic MSI-H/dMMR tumours that have 
progressed after initial treatment (45). Immune checkpoint blockade has 
been associated with immune-mediated colitis and this is particularly relevant 
for patients with co-existing inflammatory bowel disease (46). Although our 
results require validation in a randomized prospective cohort, it is exciting to 
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postulate that immune blockade therapies may be useful adjuncts in treating 
patients with dMMR (and/or hypermutator phenotype) associated IBD-CRC 
that have undergone a total colectomy as part of their treatment programme, 
negating the risk of immunotherapy mediated colitis. Importantly, immune 
therapies should be used with caution or avoided in IBD-CRC patients who 
have undergone a partial colectomy or those with Stage IV disease with an 
intact colon as it can aggravate the underlying colitis (47).  
 
To date, we have not been able to use genetic or molecular markers to 
improve the detection or treatment of IBD-CRC. In 2009, a specialist 
committee in the United States of America recommended universal screening 
for Lynch syndrome in all newly diagnosed colorectal cancers (48) and this 
has not been adopted for several reasons including financial, technical, 
ethical and health economical limitations. In the United Kingdom, the National 
Institute for Health and Care Excellence (NICE) is advocating use of 
mismatch repair immunohistochemistry on all colorectal cancers (including 
IBD cases) to detect Lynch syndrome (41). A cost effective analysis limited to 
early onset colorectal cancers suggests that this would be economically 
viable assuming that all of the necessary subsequent health interventions are 
fully implemented to reduce cancer mortality and morbidity (49). Our data 
supports this recommendation to detect dMMR in IBD-CRC, but not 
necessarily to detect Lynch syndrome as we did not identify any known 
clinically significant pathogenic germline mutations in MMR genes in this IBD-
CRC cohort. Whilst these important issues are resolved our data can be used 
Research. 
on July 31, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 27, 2018; DOI: 10.1158/1078-0432.CCR-17-3713 
 30 
to support the rational for universal testing in IBD-CRCs to profile tumours for 
the use of targeted therapies, which is not routinely undertaken at all 
institutions,  
The immunohistochemical analysis of TP53 protein has not been widely 
accepted to aid in the discrimination between dysplastic and inflamed colonic 
epithelium. Prospective studies are required to determine whether analyzing 
for TP53 abnormalities and loss of expression of MLH1 together, in colonic 
biopsies with potentially dysplastic epithelium, could aid in the evaluation of 
those at highest risk of developing CRC, similar to the molecular profiling 
used in gastric cancer (50).  
 
Our retrospective study has inherent limitations and the small sample size 
may result in a reporting bias. Notwithstanding these issues, the power of 
next-generation sequencing technology has provided detailed information 
allowing clinically relevant statistical analyses to be undertaken. Future 
similar studies may discover many more similarities and differences between 
IBD-CRC and other types of CRC. 
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CONCLUSION 
The categorisation of disease guides individualised therapeutic strategies 
and can predict the response to therapy and prognosis. Our analysis 
demonstrates that proximal IBD-CRCs have high mutational rates associated 
with defects in MMR and DNA POLE proof-reading function. This results in a 
predicted higher neo-epitope load, which could be exploited using 
immunotherapies. The hypermutator phenotype of this cohort is mostly 
associated with loss of MLH1 expression and this could be evaluated in 
colonic dysplastic lesions detected in IBD patients. The identification of driver 
genes in hypermutated IBD-CRCs can be used to develop therapeutic agents 
targeting the corresponding molecular pathways. In our series up to 90% of 
the hypermutated IBD-CRCs have actionable mutations. These approaches 
would complement and individualise current surveillance and treatment 
programmes for IBD-CRC.  
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Table 1 Mutational rates in IBD-CRC and sporadic CRC. 
 
 
TUMOUR 
PHENOTYPE 
TCGA(25) DIN ROBLES(31) 
Hypermutators >12 (728) 32.6-171.3 (56.2) 18.19-22.2 (N/A) 
Non-hypermutators 
<8.24 (58); 
Non-silent mutations only 
2.1-7.0 (3.1) 0.3-5.1 (1.3) 
 
Mutational rates (mutations/Mb) from the whole-exome sequence analysis of TCGA sporadic 
CRC cohort (25) and IBD-CRCs from this study and Robles et al. (31) in the hypermutator 
and non-hypermutator cancers. Numbers in parentheses are median mutation rates. Two 
hypermutators were present in the Robles cohort. The rates provided include total mutations 
with the exception of the median mutation rate of non-hypermutator cancers in the TCGA 
cohort. 
 
Table 2 Frequency of TP53, KRAS and APC mutations in IBD-CRC and sporadic CRC. 
 
GENE TCGA HM(25) TCGA NHM(25) DIN HM DIN NHM ROBLES NHM(31) 
TP53 20%* 60%* 33%* 79%* 63% 
KRAS 30% 43% 44% 25% 20% 
APC 51%* 81%* 33% 29% 13% 
PIK3CA 13% 23% 56% 29% 10% 
 
Mutational frequencies from the whole-exome sequence analysis of TCGA sporadic CRC 
cohort (25) and IBD-CRCs from this study and Robles et al. (31) in hypermutator (HM) and 
non-hypermutator (NHM) cancers. 
*Significant differences between HM and NHM CRCs. 
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Figure Legends 
Figure 1: Somatic mutational rates and survival analysis of IBD-CRC. 
(A). Mutational frequency in each of the 34 IBD-CRCs ordered by overall 
mutation rate. There is a clear separation between the 10 hypermutator 
cancers and the 24 non-hypermutator cancers. With the exception of 15G1, 
15G2, and 6J, the hypermutator cancers showed elevated mutation rates of 
both SNVs and InDels. No InDels were found in the exome of 21M. (B) 
Kaplan-Meier plot of overall survival stratified by cancer mutator phenotype. 
Patients with hypermutators cancers had increased survival compared with 
patients with non-hypermutator cancers (log rank test, P=.04). 
 
Figure 2: Clinical and genetic characteristics of the IBD-CRC. 
Top panel: Mutational rate of each cancer case ordered by tumour site and 
mutation rate. The red line segregates the proximal and distal bowel cancers. 
Second panel: Tumour site, Dukes’ stage, cancer type, underlying IBD, 
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immunohistochemical testing of MLH1 (MLH1 IHC) and promoter methylation 
status of MLH1 (MLH1 Pr-M). Third panel: selected genes and somatic 
nonsense, non-silent and InDel mutations. The colours indicate the predicted 
effect of the mutation on the protein sequence, and the number indicates the 
number of mutations with the same predicted effect. Note that in cases where 
a gene has multiple mutations with different predicted effects, only the effect 
type with the highest priority will be shown.  Further details are in the 
Supplementary Methods and Materials. The complete list of mutations and 
their effects is in Supplementary Tables S2A - S2B. Lower panel: 
Contribution of signatures of mutational processes (A-F) in each cancer case. 
Each signature A-F corresponds to a signature identified by Alexandrov et al. 
(Signatures 10, 1, 13/2, 17, 6 and 5, respectively) with cosine similarities 
ranging from 0.82 to 0.97 (Supplementary Table S3). 
 
Figure 3: Signatures of mutational processes in IBD-CRC. 
 (A). The somatic mutation spectra of the IBD-CRC and sporadic CRC 
datasets are represented by each of the six possible substitution types, C>A, 
C>G, C>T, T>A, T>C, T>G (including their reverse complements) in the 
context of their immediate 5’ and 3’ flanking bases, giving 96 possible motif 
combinations. For each substitution type, the 16 motifs are listed in order 
from left to right by the 5’ flanking base (A, C, G, then T), then by the 3’ 
flanking base (A, C, G, then T). The IBD-CRC panel shows the mutation 
spectrum for 34 IBD-associated colorectal cancers; the CRC (TGCA) panel 
shows the mutation spectrum for 115 colon adenocarcinomas and 267 
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rectum adenocarcinomas from downloaded from TCGA Data Portal, and the 
CRC (NHS/HPFS) panel show the mutation spectrum for a cohort of 619 
CRCs from Giannakis et al. (14). (B) Six distinct mutation signatures (A-F) 
were extracted from IBD-CRCs and on comparison with the Alexandrov 
Signatures 1 to 30 (33) using cosine similarity (Supplementary Table S3), the 
correspondence is: Signature A and Signature 10 (POLE mutations); 
Signature B and Signature 1 (age/spontaneous deamination of 5-
methylcyotosine); Signature C and Signature 13/2 (AID/APOBEC activation); 
Signature D and Signature 17 (unknown aetiology); Signature E and 
Signature 6 (mismatch repair deficiency and microsatellite instability); 
Signature F and Signature 5 (unknown aetiology; found in all cancer types). 
 
Figure 4: Hotspot microsatellite InDels, driver genes and recurrent 
somatic copy number alterations in IBD-CRC genomes.  
(A). Hotspot InDels and driver genes in IBD-CRC. Somatic SNVs and InDels 
were used to identify hotspot InDels and driver genes in hypermutator (n=9) 
and non-hypermutator cancers (n=24). Because hypermutator case 15G1 
and 15G2 were related, SNV and InDels were merged for this analysis. (B) 
Chromosome arm-level somatic copy number alterations. Shown are 
predicted SCNAs that cover at least 90% of a chromosome arm (left panel), 
and the frequency of the SCNAs in IBD-CRC (this study), and in sporadic 
CRC studies by Sheffer et al. (33)  and TCGA (25) (right panel). 
Chromosome arms are listed in descending order of frequency in IBD-CRC. 
Grey boxes in the frequency columns indicate unknown values. IBD-CRC 
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cases are ordered left to right by overall SNV and InDel mutation rate. Cases 
to the left of the dashed line are hypermutator cancers. 
 
Figure 5: Predicted HLA Class I neo-epitopes in IBD-CRCs. 
The cancers with the highest mutational rates (hypermutators) generated the 
largest number of predicted HLA Class I neo-epitopes. 
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